NOVO NORDISK INC: Head-to-head pharmacokinetic study demonstrated greater factor IX activity with Rebinyn® versus rFIXFc in people with hemophilia B

A new head-to-head pharmacokinetic study showed that adults with hemophilia B who received a single dose (50 IU/kg) of Rebinyn® [Coagulation Factor IX (Recombinant), GlycoPEGylated] achieved high factor IX activity for longer than those treated with rFIXFc [Coagulation Factor IX (Recombinant), Fc Fusion Protein]. Read More »

DAIICHI SANKYO, INC.: Daiichi Sankyo to Present New Data on Multiple Compounds Including Antibody Drug Conjugates DS-8201 and U3-1402 at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will present new data for multiple investigational compounds in the Daiichi Sankyo Cancer Enterprise pipeline at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from June 1-5 in Chicago. Read More »

VALERITAS, INC:Valeritas Announces Positive Clinical Results Across Two New Studies Evaluating V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes

Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers V-Go® Wearable Insulin Delivery device, a simple, all-in-one insulin delivery option for patients with diabetes, announced positive results were shared today from two new studies during poster presentations at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress held in Boston, Massachusetts. Read More »

TEVA PHARMACEUTICAL INDUSTRIES LTD.: Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the publication of data from the Phase III HALO study evaluating the efficacy, safety, and tolerability of both quarterly (every three months) and monthly subcutaneous dosing regimens of fremanezumab for the prevention of episodic migraine (EM). Read More »

VALERITAS, INC:Valeritas’ V-Go® Wearable Insulin Delivery Device Results in Clinical Benefits Sustained Over Time in Patients with Diabetes

Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, announced today the publication last week of a manuscript titled “Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: a Retrospective Analysis” in Advances in Therapy, an international, peer-reviewed journal. Read More »

NOVARTIS CORPORATION: Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

Novartis today announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for these patients2. Read More »

MYLAN INC: Mylan Statement on Supply of EpiPen® (epinephrine injection, USP) Auto-Injectors from Meridian Medical Technologies, a Pfizer company

The U.S. Food and Drug Administration (FDA) posted a supply notification about EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors, and the authorized generic versions of these strengths, on its website to provide greater transparency and confirm that the product remains available. Read More »